Quarterly information

2007: A further year of strong growth: up 16%

Sales growth and financial position
2007 4th quarter sales registered a further 15% growth in all markets.
2007 full-year growth was 16%, driven by the strength of the sublingual route desensitisation segment (SLIT), which grew 21%. The significant increase in the number of new patients, in particular in France and Germany, and growing sales excluding subsidiaries were the main growth drivers.
2007 results, should exceed those of 2006 (EBIT of € 23 million), in spite of a further significant increase in R&D expenses.

2008 outlook
The Group gives guidance of double-digit sales growth. 2008 results should be impacted by additional R&D investments in the US.
The questions asked by the German agency regarding the ORALAIR^® Grasses file have been dealt with and we expect a licence to be issued.
Talks are continuing with potential partners in the US.